Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUBIL: Adjuvant Durvalumab and Tremelimumab +/- Capecitabine in Biliary Tract Cancer
NCT05239169Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- May 2022
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in biliary tract cancer (BTC), sponsored by Institut für Klinische Krebsforschung. Started May 2022; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05239169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239169.